Current state of biomarker development for clinical application in epithelial ovarian cancer

Gynecologic Oncology

Volumn 116, Issue 2, 2010, Pages 240-245

  Moore, Richard G ^a   MacLaughlan, Shannon ^a   Bast Jr , Robert C ^b  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Monitoring; Ovarian cancer; Screening; Tumor marker

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; INHIBIN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; ECHOGRAPHY; ENDOMETRIOSIS; EPITHELIAL OVARIAN CANCER; HUMAN; LIVER CIRRHOSIS; MENSTRUATION; OVARY CANCER; PELVIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING; SENSITIVITY AND SPECIFICITY;

CA-125 ANTIGEN; FEMALE; HUMANS; MASS SCREENING; OVARIAN NEOPLASMS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 74249095507     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.09.041     Document Type: Review

References (70)

1. American Cancer Society Cancer Facts & Figures 2009 Atlanta: American Cancer Society 2009;1-68.
2. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. SEER Cancer Statistics Review. 2009. Ref Type: Electronic Citation.
3. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 4 (1994) 974-979
4. Young R.C., Decker D.G., Wharton J.T., Piver M.S., Sindelar W.F., Edwards B.K., et al. Staging laparotomy in early ovarian cancer. JAMA 250 22 (1983) 3072-3076
5. Carney M.E., Lancaster J.M., Ford C., Tsodikov A., and Wiggins C.L. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?. Gynecol. Oncol. 84 1 (2002) 36-42
6. Earle C.C., Schrag D., Neville B.A., Yabroff K.R., Topor M., Fahey A., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J. Natl. Cancer Inst. 98 3 (2006) 172-180
7. Goff B.A., Matthews B.J., Wynn M., Muntz H.G., Lishner D.M., and Baldwin L.M. Ovarian cancer: patterns of surgical care across the United States. Gynecol. Oncol. 103 2 (2006) 383-390
8. Goff B.A., Matthews B.J., Larson E.H., Andrilla C.H., Wynn M., Lishner D.M., et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 109 10 (2007) 2031-2042
9. Paulsen T., Kjaerheim K., Kaern J., Tretli S., and Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int. J. Gynecol. Cancer 16 Suppl. 1 (2006) 11-17
10. Guidelines for referral to a gynecologic oncologist: rationale and benefits. The Society of Gynecologic Oncologists. Gynecol. Oncol. 78 3 Pt. 2 (2000) S1-13
11. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet. Gynecol. 100 6 (2002) 1413-1416
12. Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., and Grudzinskas J.G. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br. J. Obstet. Gynaecol. 97 10 (1990) 922-929
13. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 1 (2006) 34-43
14. Bast Jr. R.C., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., and Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68 5 (1981) 1331-1337
15. Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T., et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 108 (2007) 402-408
16. Skates S.J., Menon U., MacDonald N., Rosenthal A.N., Oram D.H., Knapp R.C., et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J. Clin. Oncol. 21 10 Suppl (2003) 206-210
17. Woolas R.P., Xu F.J., Jacobs I.J., Yu Y.H., Daly L., Berchuck A., et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J. Natl. Cancer Inst. 85 21 (1993) 1748-1751
18. Partridge E., Kreimer A.R., Greenlee R.T., Williams C., Xu J.L., Church T.R., et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet. Gynecol. 113 4 (2009) 775-782
19. Einhorn N., Sjovall K., Knapp R.C., Hall P., Scully R.E., Bast Jr. R.C., et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet. Gynecol. 80 1 (1992) 14-18
20. Skates S.J., Xu F.J., Yu Y.H., Sjovall K., Einhorn N., Chang Y., et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76 10 Suppl (1995) 2004-2010
21. Menon U., Skates S.J., Lewis S., Rosenthal A.N., Rufford B., Sibley K., et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J. Clin. Oncol. 23 31 (2005) 7919-7926
22. Menon U., Gentry-Maharaj A., Hallett R., Ryan A., Burnell M., Sharma A., et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10 4 (2009) 327-340
23. Bast Jr. R.C., Badgwell D., Lu Z., Marquez R., Rosen D., Liu J., et al. New tumor markers: CA125 and beyond. Int. J. Gynecol. Cancer 15 Suppl. 3 (2005) 274-281
24. Visintin I., Feng Z., Longton G., Ward D.C., Alvero A.B., Lai Y., et al. Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 14 4 (2008) 1065-1072
25. Amonkar S., Bertenshaw G., and Chen T. Development and preliminary evaluation of a multivariant index assay for ovarian cancer. PLos ONE 4 (2009) e4599
26. Nosov V., Su F., Amneus M., Birrer M., Robins T., Kotlerman J., et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am. J. Obstet. Gynecol. 200 6 (2009) 635-639
27. Cramer D.W., Bast R.C., Clark C., Coombes K., Diamandis E., Fung E., et al. Phase III validation of ovarian cancer biomarkers in pre-diagnostic specimens from the PLCO screening trial. Proc. Am. Assoc. Cancer Res. (2009) LB-96
28. Badgwell D., Lu Z., Cole L., Fritsche H., Atkinson E.N., Somers E., et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol. Oncol. 106 3 (2007) 490-497
29. Anderson N.S., Bermudez Y., Badgwell D., Chen R., Nicosia S.V., Bast Jr. R.C., et al. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol. Oncol. 112 1 (2009) 60-67
30. Goodell V., Salazar L.G., Urban N., Drescher C.W., Gray H., Swensen R.E., et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J. Clin. Oncol. 24 5 (2006) 762-768
31. Hudson M.E., Pozdnyakova I., Haines K., Mor G., and Snyder M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc. Natl. Acad. Sci. U. S. A. 104 44 (2007) 17494-17499
32. Gunawardana C.G., Memari N., and Diamandis E.P. Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays. Clin. Biochem. 42 4-5 (2009) 426-429
33. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60 7 (2000) 1777-1788
34. Tsai-Turton M., Santillan A., Lu D., Bristow R.E., and Chan K.C. Shih I et al. p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol. Oncol. 114 1 (2009) 12-17
35. Curtin J.P. Management of the adnexal mass. Gynecol. Oncol. 55 3 Pt. 2 (1994) S42-S46
36. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol. Oncol. 55 3 Pt. 2 (1994) S4-14
37. McGowan L., Lesher L.P., Norris H.J., and Barnett M. Misstaging of ovarian cancer. Obstet. Gynecol. 65 4 (1985) 568-572
38. Einhorn N., Knapp R.C., Bast R.C., and Zurawski Jr. V.R. CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary. Acta Oncol. 28 5 (1989) 655-657
39. Hellstrom I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A., Schummer M., McIntosh M., et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63 13 (2003) 3695-3700
40. Maggino T., Gadducci A., D'Addario V., Pecorelli S., Lissoni A., Stella M., et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol. Oncol. 54 2 (1994) 117-123
41. Skates S.J., Horick N., Yu Y., Xu F.J., Berchuck A., Havrilesky L.J., et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J. Clin. Oncol. 22 20 (2004) 4059-4066
42. Malkasian Jr. G.D., Knapp R.C., Lavin P.T., Zurawski Jr. V.R., Podratz K.C., Stanhope C.R., et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am. J. Obstet. Gynecol. 159 2 (1988) 341-346
43. Alagoz T., Buller R.E., Berman M., Anderson B., Manetta A., and DiSaia P. What is a normal CA125 level?. Gynecol. Oncol. 53 1 (1994) 93-97
44. Bon G.G., Kenemans P., Verstraeten R., van Kamp G.J., and Hilgers J. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am. J. Obstet. Gynecol. 174 1 Pt. 1 (1996) 107-114
45. Einhorn N., Bast Jr. R.C., Knapp R.C., Tjernberg B., and Zurawski Jr. V.R. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet. Gynecol. 67 3 (1986) 414-416
46. Drapkin R., von Horsten H.H., Lin Y., Mok S.C., Crum C.P., Welch W.R., et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 65 6 (2005) 2162-2169
47. Huhtinen K., Suvitie P., Hiissa J., Junnila J., Huvila J., Kujari H., et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br. J. Cancer 100 8 (2009) 1315-1319
48. Shah C.A., Lowe K.A., Paley P., Wallace E., Anderson G.L., McIntosh M.W., et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol. Biomark. Prev. 18 5 (2009) 1365-1372
49. Rosen D.G., Wang L., Atkinson J.N., Yu Y., Lu K.H., Diamandis E.P., et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 99 2 (2005) 267-277
50. Bailey J., Tailor A., Naik R., Lopes A., Godfrey K., Hatem H.M., et al. Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases?. Int. J. Gynecol. Cancer 16 Suppl. 1 (2006) 30-34
51. Enakpene C.A., Omigbodun A.O., Goecke T.W., Odukogbe A.T., and Beckmann M.W. Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index. J. Obstet. Gynaecol. Res. 35 1 (2009) 131-138
52. Geomini P., Kruitwagen R., Bremer G.L., Cnossen J., and Mol B.W. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet. Gynecol. 113 2 Pt 1 (2009) 384-394
53. Tingulstad S., Hagen B., Skjeldestad F.E., Onsrud M., Kiserud T., Halvorsen T., et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br. J. Obstet. Gynaecol. 103 8 (1996) 826-831
54. Tingulstad S., Hagen B., Skjeldestad F.E., Halvorsen T., Nustad K., and Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet. Gynecol. 93 3 (1999) 448-452
55. Moore R.G., McMeekin D.S., Brown A.K., Disilvestro P., Miller M.C., Allard W.J., et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 112 1 (2009) 40-46
56. Healy D.L., Burger H.G., Mamers P., Jobling T., Bangah M., Quinn M., et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N. Engl. J. Med. 329 21 (1993) 1539-1542
57. Tsigkou A., Marrelli D., Reis F.M., Luisi S., Silva-Filho A.L., Roviello F., et al. Total inhibin is a potential serum marker for epithelial ovarian cancer. J. Clin. Endocrinol. Metab. 92 7 (2007) 2526-2531
58. Hogdall E.V., Christensen L., Kjaer S.K., Blaakaer J., Jarle I C., Gayther S., et al. Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish 'MALOVA'ovarian cancer study. Pathology 40 5 (2008) 487-492
59. Tholander B., Taube A., Lindgren A., Sjoberg O., Stendahl U., and Tamsen L. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol. Oncol. 39 1 (1990) 26-33
60. Bast Jr. R.C., Klug T.L., St John E., Jenison E., Niloff J.M., Lazarus H., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309 15 (1983) 883-887
61. Hawkins R.E., Roberts K., Wiltshaw E., Mundy J., and McCready V.R. The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma. Br. J. Cancer 60 4 (1989) 634-637
62. Moore R.G., Brown A.K., Miller C.M., Badgwell D., Lu Z., Verch T., Lu K.H., et al. A novel multiple biomarker assay for the detection of ovarian carcinoma. J. Clin. Oncol. 24 (2006) 5023
63. Brown A.K., Miller M.C., Robison K., Somers E., Altaner S., Granai C.O., et al. Differential expression of CA125 and a novel serum tumor marker HE4 in epithelial ovarian cancer. J. Clin. Oncol. 26 (2009) (20 suppl; abstr 5533)
64. Rustin G.J., Bast Jr. R.C., Kelloff G.J., Barrett J.C., Carter S.K., Nisen P.D., et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin. Cancer Res. 10 11 (2004) 3919-3926
65. Allard W.J., Somers E., Theil R., and Moore R.G. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer. J. Clin. Oncol. 26 (2009) (May 20 suppl; abstr 5535)
66. Rustin G.J., Nelstrop A.E., Tuxen M.K., and Lambert H.E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann. Oncol. 7 4 (1996) 361-364
67. Rustin G.J., Nelstrop A.E., McClean P., Brady M.F., McGuire W.P., Hoskins W.J., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol. 14 5 (1996) 1545-1551
68. Partridge E.E., and Barnes M.N. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J. Clin. 49 5 (1999) 297-320
69. Rustin G.J., and van der Burg M.E. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J. Clin. Oncol. 27 18s (2009)
70. Parmar M.K., Ledermann J.A., Colombo N., du B.A., Delaloye J.F., Kristensen G.B., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 9375 (2003) 2099-2106